# Pemvidutide vs Efinopegdutide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/pemvidutide-vs-efinopegdutide

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Pemvidutide vs Efinopegdutide

Compared side by side

# Pemvidutide vs efinopegdutide: how they differ

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Both are weekly GLP-1 and glucagon dual agonists now developed mainly for liver disease: pemvidutide, from Altimmune, is balanced 1:1 between the two receptors, and efinopegdutide, now with Merck, is tuned about 2 to 1 toward GLP-1. Neither is approved; pemvidutide’s phase 3 trial began in 2026. In people with fatty liver, pemvidutide cut liver fat by about half or more within 12 to 24 weeks, and efinopegdutide by about 73% in a 24-week trial.

## Side by side

| Compared | [Pemvidutide](https://pepvault.app/peptides/pemvidutide) | [Efinopegdutide](https://pepvault.app/peptides/efinopegdutide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | ALT-801 | MK-6024, JNJ-64565111, Efino |
| What it is | An investigational once-weekly GLP-1 and glucagon dual agonist from Altimmune, built for a gentler start: its two lower doses were given from the first injection without a dose ramp. | A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease. |
| How it works | Once-weekly GLP-1 and glucagon dual agonist from Altimmune, balanced 1:1 between the two receptors. Its EuPort domain binds albumin to slow its clearance for weekly dosing and, the company says, slows its entry into the blood, which it links to its tolerability. The GLP-1 arm curbs appetite; the glucagon arm acts directly on the liver, where it raises fat burning and curbs fat-making, and its developer now runs it mainly for liver disease. Investigational: not approved anywhere. | Once-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck. |
| Commonly reported | Very little yet; it is rarely run outside trials. | GI side effects during step-ups, and weight loss too. Not approved anywhere. |
| Studied range | Research range: 1.2–2.4 mg, starting dose 1.2 mg. Studied in research — not a recommendation. | Research range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | Not published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released | Not reported in an open human PK source; dosed once weekly in all its trials |
| Route | SubQ injection | SubQ injection |
| Typical run | Continuous weekly dosing in all its trials (12 to 48 weeks); no data on stopping or cycling. | Used continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, constipation, diarrhea | Nausea, vomiting, diarrhea |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking pemvidutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Pemvidutide

- Day 1–84 · 1.2 mg No ramp at this dose
- Day 1–84 · 1.8 mg Most side effects come early
- Day 1–112 · 2.4 mg The top dose, after a short ramp
- Day 57–168 Liver fat drops faster than weight
- Day 169–336 Most of the loss is fat

[Every card for pemvidutide, with its sources](https://pepvault.app/peptides/pemvidutide#weeks)

### Efinopegdutide

- Day 1–28 · 2 mg A gentle first month
- Day 29–364 · 4 mg Four milligrams
- Day 57–364 · 7 mg The dose the trial favoured
- Day 57–364 Weight comes down too
- Day 85–364 · 10 mg Ten milligrams: more side effects, not more benefit

[Every card for efinopegdutide, with its sources](https://pepvault.app/peptides/efinopegdutide#weeks)

## With this comparison

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [Pemvidutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)
- [Efinopegdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)
- [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026)
- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [MASH](https://pepvault.app/glossary/mash)

## Questions people ask

### How long do pemvidutide and efinopegdutide last?

The half-life of pemvidutide is not published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released. The half-life of efinopegdutide is not reported in an open human PK source; dosed once weekly in all its trials.

### How often are pemvidutide and efinopegdutide taken?

Pemvidutide: weekly. Route: SubQ injection. Efinopegdutide: weekly. Route: SubQ injection.

### How are pemvidutide and efinopegdutide dosed in research?

The research range for pemvidutide is 1.2–2.4 mg, with a 1.2 mg starting dose. The research range for efinopegdutide is 4–10 mg, with a 2 mg starting dose. Studied in research — not a recommendation.

### What are the common side effects of pemvidutide and efinopegdutide?

For pemvidutide, the library lists: nausea, vomiting, constipation, diarrhea. For efinopegdutide: nausea, vomiting, diarrhea.

## Each one in full

- [Pemvidutide: dosage, half-life & reference guide](https://pepvault.app/peptides/pemvidutide)
- [Efinopegdutide: dosage, half-life & reference guide](https://pepvault.app/peptides/efinopegdutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking pemvidutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking pemvidutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [Pemvidutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)
- [Efinopegdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)
- [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026)
- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [MASH](https://pepvault.app/glossary/mash)

<!--promo-->

PepVault for iPhone

## Taking pemvidutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
